Selinexor in multiple myeloma

Martino, Enrica Antonia; Vigna, Ernesto; Bruzzese, Antonella; Labanca, Caterina; Mendicino, Francesco; Lucia, Eugenio; Olivito, Virginia; Zimbo, Annamaria; Torricelli, Federica; Neri, Antonino; Morabito, Fortunato; Gentile, Massimo

doi:10.1080/14656566.2024.2333376

Cited by 1 publication

(1 citation statement)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the past few decades, several non-targeted drugs have been approved for the treatment of multiple myeloma, including alkylating agents [ 40 ], corticosteroids [ 41 – 43 ], immunomodulatory imide drugs (IMiDs) [ 44 – 47 ], proteasome inhibitors (PIs) [ 42 , 48 – 51 ], histone deacetylases (iHDACs) inhibitors [ 37 , 52 , 53 ], and XPO1 inhibitor [ 54 – 56 ] (Table 1 ). While these drugs have significantly extended the survival of patients with multiple myeloma by effectively killing myeloma cells and controlling disease progression, they often come with serious adverse effects due to their non-specificity.…”

Section: Introductionmentioning

confidence: 99%

Multiple myeloma: signaling pathways and targeted therapy

Lu,

Yang,

et al. 2024

Mol Biomed

View full text Add to dashboard Cite

Multiple myeloma (MM) is the second most common hematological malignancy of plasma cells, characterized by osteolytic bone lesions, anemia, hypercalcemia, renal failure, and the accumulation of malignant plasma cells. The pathogenesis of MM involves the interaction between MM cells and the bone marrow microenvironment through soluble cytokines and cell adhesion molecules, which activate various signaling pathways such as PI3K/AKT/mTOR, RAS/MAPK, JAK/STAT, Wnt/β-catenin, and NF-κB pathways. Aberrant activation of these pathways contributes to the proliferation, survival, migration, and drug resistance of myeloma cells, making them attractive targets for therapeutic intervention. Currently, approved drugs targeting these signaling pathways in MM are limited, with many inhibitors and inducers still in preclinical or clinical research stages. Therapeutic options for MM include non-targeted drugs like alkylating agents, corticosteroids, immunomodulatory drugs, proteasome inhibitors, and histone deacetylase inhibitors. Additionally, targeted drugs such as monoclonal antibodies, chimeric antigen receptor T cells, bispecific T-cell engagers, and bispecific antibodies are being used in MM treatment. Despite significant advancements in MM treatment, the disease remains incurable, emphasizing the need for the development of novel or combined targeted therapies based on emerging theoretical knowledge, technologies, and platforms. In this review, we highlight the key role of signaling pathways in the malignant progression and treatment of MM, exploring advances in targeted therapy and potential treatments to offer further insights for improving MM management and outcomes.

show abstract